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Letters to the EditorVinyl chloride and the liver: Misrepresentation of
epidemiological evidenceTo the Editor:
In reviewing the epidemiological literature on vinyl chloride
monomer (VCM) and hepatocellular carcinoma (HCC), Sherman
incurred errors and misrepresentation of the overall evidence [1].
First, the author provides a surprising estimate of an annual
incidence of liver angiosarcoma (LAS) among US exposed workers
equal to 0.014/100,000. This is probably the incidence of LAS in
the US general population which was about 0.014–0.025/
100,000 in 1964–1974 [2]. Indeed, the mortality (close to inci-
dence) rate was 15.2/100,000 (48 cases in 316,520 person-years)
in the North American cohort of VCM workers [3], three orders of
magnitude higher than that reported by Sherman.
Second, the author contradicts himself in regards to the asso-
ciation between VCM and HCC in the European cohort [4], afﬁrm-
ing, on page 1077, that ‘‘this study did not suggest that there was
a dose–response relationship between exposure and the develop-
ment of HCC”, and on page 1080 that ‘‘there seems to be a trend
towards a higher HCC death rate with increasing dose”.
Third, our case–control study [5] was presented as a ‘‘cohort
study” on page 1078, while on page 1077 the study from Ward
(cohort study) [4] and that from Boffetta (meta-analysis of cohort
studies) [6] were confused with ‘‘case–control studies”. In the
same statement, Sherman afﬁrms that ‘‘case–control studies”
use ‘‘non-exposed workers as controls”. This is similarly incor-
rect, since controls in a case–control study are subjects without
disease and not without exposure.
Fourth, he reports that case–control studies used ofﬁce work-
ers as controls, with non-comparability with cases in regards to
viral hepatitis and alcohol consumption. This is not true, as the
only case–control study that he cites is our study [5], where cases
and controls were all blue-collar workers coming from the same
VCM plant.
Fifth, he claims that in our analyses when examining interac-
tions, each cell contained 10 or fewer cases, making results unre-
liable even if statistically signiﬁcant. Nonetheless, if the reader
does not like the analysis of interactions, he can rely on the full
analysis of thirteen cases of HCC and 40 cases of liver cirrhosis
(LC), that were separately compared to 139 referents without
chronic liver diseases or cancer in a case–control study nested
in a cohort of 1658 VCM workers. By holding the confounding
factors (alcohol, age, markers of B/C viruses) constant at logistic
regression, each extra increase of 1000 ppm  years of VCM
cumulative exposure was found to increase the risk of HCC by
71% (odds ratio, OR = 1.71; 95% conﬁdence interval, CI = 1.28–
2.44) and the risk of LC by 37% (OR = 1.37; CI = 1.13–1.69) [5].
Sixth, Sherman reports that results from our study are doubt-
ful because cumulative exposure was associated with cirrhosis
but is also a function of age. Indeed, our analyses were stratiﬁed
for year of birth (controlling for age carried similar results). Fur-
thermore, he states that the same objection applies to the studyJournal of Hepatology 2of Pirastu et al. [7]. This does not make sense, since this was a
cohort study where the measure of association (standardized
mortality ratio) takes into account age and calendar period.
Seventh, Sherman claims that an ascertainment bias couldhave
affected the diagnosis of HCC in the epidemiological studies
reviewed since they rely upon death certiﬁcates and not ‘‘upon
autopsy data, biopsy data, angiography or a diagnostic elevated
AFP” (alpha-fetoprotein, a serological marker of HCC, is rarely
increased in LAS). In our study [5], however, out of 13 cases of
HCC, eight were conﬁrmed by histology and ﬁve based on the cri-
teria – focal hepatic lesions at ultrasonography and alpha-fetopro-
tein greater than 400 lg/L – issued by the Italian Association Study
of Liver and British Society of Gastroenterology [8].
The author declares in a footnote to be ‘‘consultant to the
European Council of Vinyl Manufacturer’s for the workshop on
the relationship between VCM and HCC” [1]. Furthermore, in
his conclusion Sherman cites as supporting evidence only two
papers [9,10] – two reviews both written by consultants of the
vinyl chloride industry in a lawsuit against the management of
a VCM plant. We think that a conﬂict of interests does not repre-
sent a fatal ﬂaw for research until it does not heavily affect the
quality of papers. Moreover, in such a speciﬁc matter it is difﬁcult
not to have some conﬂict of interest: two authors (G.M. and D.M.)
of the present letter were consultants of Public Prosecutors in the
above lawsuit.
With his paper carrying errors and inconsistencies, Sherman
concludes that the relation between VCM and HCC remains
‘‘unproven”. This is a misrepresentation of the current epidemio-
logical evidence that, according to the International Agency for
Research on Cancer, there is ‘‘sufﬁcient evidence” that exposure
to vinyl chloride in humans causes both HCC and LAS [11].
Conﬂict of interests
Two of the authors (G.M. and D.M.) were consultants of Italian
Government and Public Prosecutors in a lawsuit opposing work-
ers, local municipalities, and the Italian Government against the
management of an Italian vinyl chloride plant.
References
[1] Sherman M. Vinyl chloride and the liver. J Hepatol 2009;51:1074–1081.
[2] Falk H, Herbert J, Crowley S, Ishak KG, Thomas LB, Popper H, et al.
Epidemiology of epatic angiosarcoma in the United States 1964–1974.
Environ Health Perspect 1981;41:107–113.
[3] Mundt KA, Dell LD, Austin RP, Luippold RS, Noess R, Bieglow C. Historical
cohort study of 10,109 men in the North American vinyl chloride industry,
1942–72: update of cancer mortality to 31 December 1995. Occup Environ
Med 2000;57:774–781.010 vol. 52 j 776–778
JOURNAL OF HEPATOLOGY
[4] Ward E, Boffetta P, Andersen A, Colin D, Comba P, Deddens JA, et al.
Update of the follow-up of mortality and cancer incidence among
European workers employed in the vinyl chloride industry. Epidemiology
2001;12:710–718.
[5] Mastrangelo G, Fedeli U, Fadda E, Valentini F, Agnesi R, Magarotto G, et al.
Increased risk of hepatocellular carcinoma and liver cirrhosis in vinyl
chloride workers: synergistic effect of occupational exposure with alcohol
intake. Environ Health Perspect 2004;112:1188–1192.
[6] Boffetta P, Matisane L, Mundt KA, Dell LD. Meta-analysis of studies of
occupational exposure to vinyl chloride in relation to cancer mortality.
Scand J Work Environ Health 2003;29:220–229.
[7] Pirastu R, Baccini M, Biggeri A, Comba P. Epidemiologic study of workers
exposed to vinyl chloride in Porto Marghera: mortality update. Epidemiol
Prev 2003;27:161–172.
[8] Ryder SD. Guidelines for the diagnosis and treatment of hepatocellular
carcinoma (HCC) in adults. Gut 2003;52 (Suppl. 3):1–8.
[9] Dragani TA, Zocchetti C. Occupational exposure to vinyl chloride and risk of
hepatocellular carcinoma. Cancer Causes Control 2008;19:1193–1200.
[10] McLaughlin JK, Lipworth L. A critical review of the epidemiologic literature
on health effects of occupational exposure to vinyl chloride. J Epidemiol
Biostat 1999;4:253–275.Selective rather than routine app
cholangio-pancreatography in
To the Editor:
Petersen and colleagues describe their experience in the ‘‘routine”
useof endoscopic retrogradecholangio-pancreatography (ERCP) in
childrenawaitingexplorative laparotomy(EL) for suspectedbiliary
atresia (BA) [1]. They report that almost 25% of the infants have
avoided surgery after documenting a patent biliary tree. The
quoted speciﬁcity of ERCP in diagnosing BA was 73% [1].
The aim of avoiding unnecessary surgery is valiant and
undoubted, but we feel that a non-selective approach to a rela-
tively invasive procedure in jaundiced infants, who may be recov-
ering from the potentially recoverable liver injury, such as the
one secondary to prematurity, total parenteral nutrition, severe
haemolysis and/or infection, may not be justiﬁed. Repeated gen-
eral anaesthetic, required by combined ERCP/EL, in a jaundiced
child carries additional risks outside the usual economic argu-
ments. Sixty (43%) infants referred to Petersen et al. who under-
went ERCP actually did not have BA. Suspected BA may mean
different things for different centres and submitting all referred
children to ERCP may not be indicated, despite the technical
excellence.
In this study the ‘‘pre-selection” information, including ultra-
soundﬁndings or liver histology, was unfortunately not presented,
although the authors have quoted experiences where speciﬁcity
for percutaneous liver biopsy was 96% [2] and 89% [3], respec-
tively. An early study from our centre found the liver histology
as sufﬁcient for diagnosis of BA in 86% infants with neonatal cho-
lestasis [4]. Finally, in the study by Petersen et al. the children
undergoing ERCP/EL combination were up to 174 days old, an
age where beneﬁts of corrective surgery are somewhat dubious.
We have recently reported our own tertiary centre experience
on use of ERCP in 48 cholestatic infants younger than 100 days,
representing only around 4% of infants with neonatal cholestasis,
where diagnosis after comprehensive hepatological work-up
remained unclear [5]. EL was avoided in 42% of children, while
selective ERCP had a speciﬁcity of 87% for diagnosis of BA [5].
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Protocols for investigating infants with prolonged neonatal
cholestasis will continue to differ from centre to centre, but there
is no substitute for evaluation of all the available clinical informa-
tion, including monitoring stool colour and its change on chole-
retics [6]. ERCP is a very welcome addition to the diagnostic
algorithm for the diagnosis of BA, but in our view should be used
selectively once other, less invasive, tests have proven
inconclusive.
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